<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology and pathogenesis of portal vein thrombosis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology and pathogenesis of portal vein thrombosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology and pathogenesis of portal vein thrombosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arun J Sanyal, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H417351817"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The portal vein is formed by the confluence of the splenic and superior mesenteric veins, which drain the spleen and small intestine, respectively (<a class="graphic graphic_figure graphicRef68680" href="/z/d/graphic/68680.html" rel="external">figure 1</a>). Portal hypertension develops as a result of obstruction to flow within the portal venous system. It can be categorized as prehepatic, intrahepatic, or posthepatic based upon the site of obstruction to flow (<a class="graphic graphic_table graphicRef76516" href="/z/d/graphic/76516.html" rel="external">table 1</a>). The intrahepatic causes of portal hypertension have been further subdivided as presinusoidal, sinusoidal, or postsinusoidal based on the location of the obstruction to portal blood flow within the liver. Causes of extrahepatic portal vein obstruction include thrombosis and invasion or constriction by a malignant tumor.</p><p>This topic will review portal vein thrombosis (PVT), the most common cause of extrahepatic portal vein obstruction. Other important causes of noncirrhotic portal hypertension (including noncirrhotic portal fibrosis and schistosomiasis) and the clinical manifestations, diagnosis, and treatment of acute and chronic PVT are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3580.html" rel="external">"Noncirrhotic portal hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/3579.html" rel="external">"Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/88014.html" rel="external">"Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H417347098"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of PVT among patients without cirrhosis is unclear. It is thought to account for 5 to 10 percent of patients with portal hypertension in developed countries and up to a third of patients in developing countries (because of an increased frequency of infectious complications that predispose to PVT) [<a href="#rid1">1,2</a>]. Among patients with cirrhosis, PVT is common and is associated with the severity of the patient's liver disease [<a href="#rid3">3,4</a>]. Autopsy studies have reported prevalences of 6 to 64 percent, whereas studies that used ultrasonography to diagnose PVT reported prevalences of 5 to 24 percent [<a href="#rid5">5</a>]. The prevalence of PVT is estimated to be less than 1 percent in patients with compensated cirrhosis, but is 8 to 25 percent in patients who are candidates for liver transplantation [<a href="#rid6">6,7</a>]. </p><p>In a study of almost 24,000 autopsies in Sweden performed between 1970 and 1982, the prevalence of PVT was 1 percent [<a href="#rid8">8</a>]. The most common predisposing conditions for PVT were cirrhosis (28 percent), primary or secondary hepatobiliary malignancy (23 and 44 percent, respectively), major infectious or inflammatory abdominal disease (10 percent), or a myeloproliferative disorder (3 percent). However, no predisposing factors were identified in 14 percent.</p><p class="headingAnchor" id="H417347105"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Portal vein thrombosis (PVT) in patients with a previously healthy liver is thought to be due to inherited or acquired prothrombotic states [<a href="#rid9">9</a>] (<a class="graphic graphic_table graphicRef73799" href="/z/d/graphic/73799.html" rel="external">table 2</a>). However, no apparent cause for PVT is identified in more than 25 percent of patients [<a href="#rid10">10-12</a>]. Among patients with cirrhosis, the pathogenesis is likely related to unbalanced hemostasis and slowing of portal flow [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a> and  <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"</a>.)</p><p>Inherited conditions associated with PVT include [<a href="#rid3">3,14-20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Factor V Leiden </p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin gene mutation </p><p class="bulletIndent1"><span class="glyph">●</span>Protein C deficiency </p><p class="bulletIndent1"><span class="glyph">●</span>Protein S deficiency </p><p class="bulletIndent1"><span class="glyph">●</span>Antithrombin deficiency </p><p class="bulletIndent1"><span class="glyph">●</span>Increased factor VIII levels</p><p></p><p>The relative frequency of prothrombotic disorders in patients with PVT is illustrated by observations from two series:</p><p class="bulletIndent1"><span class="glyph">●</span>In a case-control study of patients with cirrhosis, prothrombotic states were more common in the 23 patients with PVT than in the 40 patients without PVT, including mutations in factor V Leiden (13 versus 7.5 percent), the prothrombin gene (35 versus 2.5 percent), and the <em>MTHFR </em>gene (44 versus 5 percent) [<a href="#rid14">14</a>]. Overall, a thrombophilic genotype was detected in 70 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second study compared 65 patients with PVT without overt neoplastic disease or cirrhosis with 500 patients with lower limb deep vein thrombosis (DVT) and 700 healthy controls [<a href="#rid18">18</a>]. At least one thrombophilic abnormality was detected in 40 percent of patients with PVT or DVT, compared with only 13 percent of controls. PVT was associated with the prothrombin gene mutation and deficiencies of antithrombin, protein C, and protein S. Prothrombin gene mutations were more likely in those with PVT than in those with DVT. (See  <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">"Prothrombin G20210A"</a>.)</p><p></p><p>Acquired conditions associated with PVT include [<a href="#rid15">15,18,21-28</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Cirrhosis</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatocellular carcinoma</p><p class="bulletIndent1"><span class="glyph">●</span>Philadelphia-chromosome negative chronic myeloproliferative disorders (polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, unclassifiable myeloproliferative disorders) (see  <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Antiphospholipid syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Paroxysmal nocturnal hemoglobinuria</p><p class="bulletIndent1"><span class="glyph">●</span>Behçet syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Recent pregnancy or oral contraceptive use</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal inflammatory lesions including infection, pancreatitis, and inflammatory bowel disease</p><p class="bulletIndent1"><span class="glyph">●</span>Trauma</p><p></p><p>Procedures that have been associated with PVT include [<a href="#rid15">15,23,26,29-32</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal surgery or surgical injury of the portal vein axis</p><p class="bulletIndent1"><span class="glyph">●</span>Endoscopic sclerotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Transjugular intrahepatic portosystemic shunt</p><p class="bulletIndent1"><span class="glyph">●</span>Splenectomy</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic resection</p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatic islet cell transplantation</p><p></p><p>Patients often have multiple risk factors for PVT, so in general, PVT should not be attributed to a single etiology without first evaluating for other predisposing conditions [<a href="#rid15">15,18,21</a>]. In a study of 92 patients with portal vein thrombosis, zero, one, two, three, or four simultaneous acquired or inherited risk factors were seen in 16, 47, 24, 10, and 3 percent of patients, respectively [<a href="#rid15">15</a>]. Among patients with cirrhosis, patients with PVT are more likely than patients without PVT to have mutations associated with prothrombotic states (factor V Leiden, <em>MTHFR</em>, and prothrombin gene mutations) [<a href="#rid3">3,14,33</a>].</p><p class="headingAnchor" id="H417347119"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Portal vein thrombosis can lead to complications such as intestinal ischemia, portal hypertension, and portal cholangiopathy.</p><p class="headingAnchor" id="H417347126"><span class="h2">Intestinal ischemia</span><span class="headingEndMark"> — </span>Extensive thrombosis involving the mesenteric venous arches may lead to intestinal ischemia and eventually infarction [<a href="#rid34">34,35</a>]. This is typically seen in acute PVT because collaterals have not yet developed. The ischemia is likely related to obstruction of mesenteric venous outflow and reflex arterial constriction and occlusion. (See  <a class="medical medical_review" href="/z/d/html/91220.html" rel="external">"Mesenteric venous thrombosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3579.html" rel="external">"Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H417347133"><span class="h2">Septic portal vein thrombosis</span><span class="headingEndMark"> — </span>Septic portal vein thrombosis (acute pylephlebitis) occurs when PVT develops in a patient with an abdominal focus of infection, though the source of the infection may be difficult to find. Typically, the infection is with <em>Bacteroides fragilis</em> or <em>Escherichia coli, </em>though other pathogens have also been found. (See  <a class="medical medical_review" href="/z/d/html/2713.html" rel="external">"Pylephlebitis", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/z/d/html/2713.html" rel="external">"Pylephlebitis", section on 'Microbiology'</a>.)</p><p class="headingAnchor" id="H417347140"><span class="h2">Portal hypertension</span><span class="headingEndMark"> — </span>Portal hypertension is responsible for the majority of the complications seen in patients with chronic PVT. It also leads to the formation of collaterals around the obstructed portal vein, known as a cavernous transformation of the portal vein or portal cavernoma.</p><p class="headingAnchor" id="H8074937"><span class="h3">Portal hemodynamics</span><span class="headingEndMark"> — </span>Portal venous pressure is determined by the product of portal venous flow and the resistance to outflow from the portal venous system:</p><p class="bulletIndent1"><span class="glyph">●</span>Portal pressure = portal venous flow x portal venous outflow resistance</p><p></p><p>Portal hypertension is defined by a hepatic venous pressure gradient (HVPG) greater than 5 mmHg. It is usually caused by an increase in resistance in the portal-hepatic vascular bed due to obstruction to flow. In patients with PVT, it occurs because of obstruction to flow in the portal vein. (See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Complications of portal hypertension'</a>.)</p><p>Differences in portal hemodynamics in the settings of acute and chronic portal vein occlusion have been studied in animal models. One model involved acutely clamping the portal vein [<a href="#rid36">36</a>]. This produced a reflex increase in splanchnic arteriolar tone that decreased flow into the portal vein and tended to nullify the effects of increased portal venous resistance from the clamp [<a href="#rid36">36</a>]. On the other hand, in an animal model of chronic portal vein stenosis, there was a paradoxical decrease in splanchnic arteriolar tone leading to increased portal flow, which compounded and perpetuated the portal hypertensive state and contributed to the hyperdynamic circulation associated with portal hypertension [<a href="#rid37">37</a>]. </p><p>The hyperdynamic circulation in the portal vein stenosis model was less prominent than that seen in cirrhosis, a setting in which increased production of nitric oxide also contributes [<a href="#rid38">38</a>]. The reasons for this difference are not well understood. While it has been hypothesized that impaired hepatic reticuloendothelial function allows bacteria and endotoxins to reach the systemic circulation and activate nitric oxide production, experimental models do not support a role of endotoxin in prehepatic portal hypertension [<a href="#rid39">39</a>]. Rather than an endotoxin-induced increase in iNOS (the inducible form of NO synthetase), it is the constitutively expressed NO synthetase (eNOS) that is increased [<a href="#rid38">38,40,41</a>].</p><p class="headingAnchor" id="H8074930"><span class="h3">Varices</span><span class="headingEndMark"> — </span>Patients with PVT frequently form varices [<a href="#rid42">42</a>]. When only a segment of the portal venous bed is obstructed, varices develop only in areas that decompress the corresponding segment. As an example, segmental portal hypertension within the splenic vein (splenic vein thrombosis) is associated with the formation of isolated gastric varices in the fundus of the stomach (<a class="graphic graphic_picture graphicRef58644" href="/z/d/graphic/58644.html" rel="external">picture 1</a>). On the other hand, patients with portal vein thrombosis commonly form varices in sites other than the esophagus and stomach (ectopic varices) [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H8074923"><span class="h3">Ascites</span><span class="headingEndMark"> — </span>Sinusoidal portal hypertension (portal pressure &gt;12 mmHg) is usually required for the formation of ascites. Thus, patients with isolated presinusoidal or prehepatic portal hypertension (as is seen with PVT) typically do not have significant ascites unless they develop acute dilutional hypoalbuminemia during fluid resuscitation for a variceal bleed or have associated cirrhosis. By contrast, ascites more readily forms in postsinusoidal and posthepatic portal hypertension (eg, from Budd-Chiari syndrome), even in the absence of well-established cirrhosis. (See  <a class="medical medical_review" href="/z/d/html/1259.html" rel="external">"Pathogenesis of ascites in patients with cirrhosis"</a>.)</p><p class="headingAnchor" id="H417347147"><span class="h2">Portal cholangiopathy</span><span class="headingEndMark"> — </span>Portal cholangiopathy (also referred to as portal biliopathy) is a complication that may be seen in patients with longstanding PVT. Portal cholangiopathy develops when the venous collaterals that form in the setting of portal hypertension compress and deform the large bile ducts [<a href="#rid44">44,45</a>]. It has been hypothesized that this may lead to stricture formation, fibrous scarring of the porta hepatis, and ischemic injury to the bile ducts resulting in stricture formation and caliber irregularity. Patients with portal cholangiopathy may develop biliary complications including pruritus, obstructive jaundice, cholecystitis, and cholangitis [<a href="#rid44">44-50</a>]. (See  <a class="medical medical_review" href="/z/d/html/88014.html" rel="external">"Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H417351609"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Portal hypertension develops as a result of obstruction to flow within the portal venous system. It can be categorized as prehepatic, intrahepatic, or posthepatic based upon the site of obstruction to flow (<a class="graphic graphic_table graphicRef76516" href="/z/d/graphic/76516.html" rel="external">table 1</a>). As a general rule, the clinical consequences of portal hypertension are similar regardless of the cause or site of obstruction. Portal vein thrombosis (PVT) is the most common cause of extrahepatic portal vein obstruction. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of PVT among patients without cirrhosis is unclear. It is thought to account for 5 to 10 percent of patients with portal hypertension in developed countries and up to a third of patients in developing countries. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with cirrhosis, PVT is common and is associated with the severity of the patient's liver disease. The prevalence of PVT is estimated to be less than 1 percent in patients with compensated cirrhosis, but it is 8 to 25 percent in patients who are candidates for liver transplantation. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PVT in a patient with a previously healthy liver is thought to be due to inherited or acquired prothrombotic states (<a class="graphic graphic_table graphicRef73799" href="/z/d/graphic/73799.html" rel="external">table 2</a>). However, no apparent cause for PVT is identified in more than 25 percent of patients. (See <a class="local">'Pathogenesis'</a> above and  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a> and  <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with cirrhosis, the pathogenesis of PVT is likely related to unbalanced hemostasis and slowing of portal flow. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PVT can lead to complications such as intestinal ischemia, portal hypertension, and portal cholangiopathy. (See <a class="local">'Complications'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Valla DC, Condat B, Lebrec D. Spectrum of portal vein thrombosis in the West. J Gastroenterol Hepatol 2002; 17 Suppl 3:S224.</a></li><li><a class="nounderline abstract_t">Sarin SK, Sollano JD, Chawla YK, et al. Consensus on extra-hepatic portal vein obstruction. Liver Int 2006; 26:512.</a></li><li><a class="nounderline abstract_t">Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40:736.</a></li><li><a class="nounderline abstract_t">Orloff MJ, Orloff MS, Orloff SL, Girard B. Portal vein thrombosis in cirrhosis with variceal hemorrhage. J Gastrointest Surg 1997; 1:123.</a></li><li><a class="nounderline abstract_t">Fimognari FL, Violi F. Portal vein thrombosis in liver cirrhosis. Intern Emerg Med 2008; 3:213.</a></li><li><a class="nounderline abstract_t">Okuda K, Ohnishi K, Kimura K, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985; 89:279.</a></li><li><a class="nounderline abstract_t">Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54:691.</a></li><li><a class="nounderline abstract_t">Ogren M, Bergqvist D, Björck M, et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006; 12:2115.</a></li><li><a class="nounderline abstract_t">Kumar A, Sharma P, Arora A. Review article: portal vein obstruction--epidemiology, pathogenesis, natural history, prognosis and treatment. Aliment Pharmacol Ther 2015; 41:276.</a></li><li><a class="nounderline abstract_t">Belli L, Romani F, Riolo F, et al. Thrombosis of portal vein in absence of hepatic disease. Surg Gynecol Obstet 1989; 169:46.</a></li><li><a class="nounderline abstract_t">Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010; 51:210.</a></li><li><a class="nounderline abstract_t">Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94:1063.</a></li><li><a class="nounderline abstract_t">Shukla A, Giri S. Portal Vein Thrombosis in Cirrhosis. J Clin Exp Hepatol 2022; 12:965.</a></li><li><a class="nounderline abstract_t">Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31:345.</a></li><li><a class="nounderline abstract_t">Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96:2364.</a></li><li><a class="nounderline abstract_t">Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost 2008; 99:675.</a></li><li><a class="nounderline abstract_t">Chamouard P, Pencreach E, Maloisel F, et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999; 116:144.</a></li><li><a class="nounderline abstract_t">Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005; 41:603.</a></li><li><a class="nounderline abstract_t">Koshy A, Jeyakumari M. High FVIII level is associated with idiopathic portal vein thrombosis in South India. Am J Med 2007; 120:552.e9.</a></li><li><a class="nounderline abstract_t">Qi X, Ren W, De Stefano V, Fan D. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12:1801.</a></li><li><a class="nounderline abstract_t">Denninger MH, Chaït Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31:587.</a></li><li><a class="nounderline abstract_t">Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44:1528.</a></li><li><a class="nounderline abstract_t">Amitrano L, Guardascione MA, Scaglione M, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol 2007; 102:2464.</a></li><li><a class="nounderline abstract_t">Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111:4922.</a></li><li><a class="nounderline abstract_t">Bergamaschi GM, Primignani M, Barosi G, et al. MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. Blood 2008; 111:4418.</a></li><li><a class="nounderline abstract_t">Janssen HL, Wijnhoud A, Haagsma EB, et al. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 2001; 49:720.</a></li><li><a class="nounderline abstract_t">Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 2013; 162:730.</a></li><li><a class="nounderline abstract_t">Khoury T, Massarwa M, Hazou W, et al. Acute Portal Vein Thrombosis Predicts Concomitant Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients. J Gastrointest Cancer 2019; 50:759.</a></li><li><a class="nounderline abstract_t">Pietrabissa A, Moretto C, Antonelli G, et al. Thrombosis in the portal venous system after elective laparoscopic splenectomy. Surg Endosc 2004; 18:1140.</a></li><li><a class="nounderline abstract_t">Romano F, Caprotti R, Scaini A, et al. Elective laparoscopic splenectomy and thrombosis of the spleno-portal axis: a prospective study with ecocolordoppler ultrasound. Surg Laparosc Endosc Percutan Tech 2006; 16:4.</a></li><li><a class="nounderline abstract_t">Yoshiya S, Shirabe K, Nakagawara H, et al. Portal vein thrombosis after hepatectomy. World J Surg 2014; 38:1491.</a></li><li><a class="nounderline abstract_t">White SA, London NJ, Johnson PR, et al. The risks of total pancreatectomy and splenic islet autotransplantation. Cell Transplant 2000; 9:19.</a></li><li><a class="nounderline abstract_t">Amitrano L, Brancaccio V, Guardascione MA, et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy 2002; 34:535.</a></li><li><a class="nounderline abstract_t">McKinsey JF, Gewertz BL. Acute mesenteric ischemia. Surg Clin North Am 1997; 77:307.</a></li><li><a class="nounderline abstract_t">Grendell JH, Ockner RK. Mesenteric venous thrombosis. Gastroenterology 1982; 82:358.</a></li><li><a class="nounderline abstract_t">Witte CL, Witte MH, Bair G, et al. Experimental study of hyperdynamic vs. stagnant mesenteric blood flow in portal hypertension. Ann Surg 1974; 179:304.</a></li><li><a class="nounderline abstract_t">Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244:G52.</a></li><li><a class="nounderline abstract_t">Niederberger M, Ginés P, Martin PY, et al. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepatology 1996; 24:947.</a></li><li><a class="nounderline abstract_t">Chu CJ, Lee FY, Wang SS, et al. Evidence against a role for endotoxin in the hyperdynamic circulation of rats with prehepatic portal hypertension. J Hepatol 1999; 30:1105.</a></li><li><a class="nounderline abstract_t">Tsai MH, Iwakiri Y, Cadelina G, et al. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003; 125:1452.</a></li><li><a class="nounderline abstract_t">Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999; 276:G1043.</a></li><li><a class="nounderline abstract_t">Alam H, Kim D, Provido H, Kirkpatrick J. Portal vein thrombosis in the adult: surgical implications in an era of dynamic imaging. Am Surg 1997; 63:681.</a></li><li class="breakAll">Burroughs AK, Bosch J. Clinical manifestations and management of bleeding episodes in cirrhotics. In: Oxford Textbook of Hepatology, McIntyre N, Benhamou JP (Eds), Oxford Scientific, 1990. p.408.</li><li><a class="nounderline abstract_t">Condat B, Vilgrain V, Asselah T, et al. Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study. Hepatology 2003; 37:1302.</a></li><li><a class="nounderline abstract_t">Khuroo MS, Yattoo GN, Zargar SA, et al. Biliary abnormalities associated with extrahepatic portal venous obstruction. Hepatology 1993; 17:807.</a></li><li><a class="nounderline abstract_t">Chattopadhyay S, Nundy S. Portal biliopathy. World J Gastroenterol 2012; 18:6177.</a></li><li><a class="nounderline abstract_t">Malkan GH, Bhatia SJ, Bashir K, et al. Cholangiopathy associated with portal hypertension: diagnostic evaluation and clinical implications. Gastrointest Endosc 1999; 49:344.</a></li><li><a class="nounderline abstract_t">Dilawari JB, Chawla YK. Pseudosclerosing cholangitis in extrahepatic portal venous obstruction. Gut 1992; 33:272.</a></li><li><a class="nounderline abstract_t">Dhiman RK, Puri P, Chawla Y, et al. Biliary changes in extrahepatic portal venous obstruction: compression by collaterals or ischemic? Gastrointest Endosc 1999; 50:646.</a></li><li><a class="nounderline abstract_t">Sarin SK, Bhatia V, Markwane U. Portal biliopathy in extra hepatic portal vein obstruction. Indian J Gastroenterol 1992; 2:A82.</a></li></ol></div><div id="topicVersionRevision">Topic 88016 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472940" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Spectrum of portal vein thrombosis in the West.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16761994" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Consensus on extra-hepatic portal vein obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15094219" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9834338" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Portal vein thrombosis in cirrhosis with variceal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18274708" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Portal vein thrombosis in liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4007419" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15831918" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16610067" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25475582" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Review article: portal vein obstruction--epidemiology, pathogenesis, natural history, prognosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2787060" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Thrombosis of portal vein in absence of hepatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821530" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3345875" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35677518" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Portal Vein Thrombosis in Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655256" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11001884" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18392325" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869612" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Frequent factor II G20210A mutation in idiopathic portal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15726653" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk factors for thrombophilia in extrahepatic portal vein obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17524760" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : High FVIII level is associated with idiopathic portal vein thrombosis in South India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24793031" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706547" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133457" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17958760" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prognostic factors in noncirrhotic patients with splanchnic vein thromboses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18250227" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18398061" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11600478" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Extrahepatic portal vein thrombosis: aetiology and determinants of survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855810" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Splanchnic vein thrombosis in myeloproliferative neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30043228" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acute Portal Vein Thrombosis Predicts Concomitant Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15156376" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Thrombosis in the portal venous system after elective laparoscopic splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16552370" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Elective laparoscopic splenectomy and thrombosis of the spleno-portal axis: a prospective study with ecocolordoppler ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24407940" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Portal vein thrombosis after hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10784062" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The risks of total pancreatectomy and splenic islet autotransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12170404" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9146714" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute mesenteric ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7033036" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mesenteric venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4813477" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Experimental study of hyperdynamic vs. stagnant mesenteric blood flow in portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6849394" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855203" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406190" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Evidence against a role for endotoxin in the hyperdynamic circulation of rats with prehepatic portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14598261" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10198349" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9247433" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Portal vein thrombosis in the adult: surgical implications in an era of dynamic imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9247433" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Portal vein thrombosis in the adult: surgical implications in an era of dynamic imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12774008" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491448" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Biliary abnormalities associated with extrahepatic portal venous obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23180936" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Portal biliopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10049418" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cholangiopathy associated with portal hypertension: diagnostic evaluation and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1541425" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pseudosclerosing cholangitis in extrahepatic portal venous obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10536320" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Biliary changes in extrahepatic portal venous obstruction: compression by collaterals or ischemic?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Portal biliopathy in extra hepatic portal vein obstruction</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
